A Phase I, Open-label, Single-center, Single/Multiple-dose, Dose-escalation/Dose-expansion Clinical Study on Tolerance and Pharmacokinetics of HWH340 Tablet in Patients With Advanced Solid Tumors
Latest Information Update: 02 Feb 2022
At a glance
- Drugs HWH-340 (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- 12 Feb 2020 Planned number of patients changed from 45 to 85.
- 12 Feb 2020 Planned End Date changed from 30 Jun 2019 to 30 Sep 2021.
- 12 Feb 2020 Planned primary completion date changed from 30 Jun 2019 to 30 Mar 2021.